New combo therapy aims to boost radiation for tough pancreatic tumors
NCT ID NCT07157033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participants to find the safest dose and check for early signs of tumor control. The main goal is to see if the combination is safe and tolerable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XER-001 (amifostine delivered via a tube from the nose to the small intestine)
What this could lead to
If it works, this could point toward a way to make radiation therapy safer and more effective for people with locally advanced pancreatic cancer.
What could go wrong
This is a very early, small trial (36 people) focused on safety and finding the right dose. It may not show clear benefit, and side effects from the drug or radiation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIty of Hope
RECRUITINGIrvine, California, 92618, United States
Contact
Contact Email: •••••@•••••
-
Christus St. Vincent Regional Cancer Center
RECRUITINGSanta Fe, New Mexico, 87505, United States
Contact
Contact Email: •••••@•••••
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Email: •••••@•••••
Contact
-
Oncology Consultants, P.A.
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Email: •••••@•••••